Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29735061 | 0.74 | ROCK2 (0.40) | — | |
| SCHEMBL10905707 | 0.69 | MTNR1A (0.65) | MTNR1AMTNR1BHTR1AMEN1ALDH1A1 | |
| SCHEMBL29361577 | 0.69 | AR (0.42) | — | |
| SCHEMBL7054082 | 0.69 | MTNR1A (0.66) | MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL24572813 | 0.68 | MAPT (0.48) | ALOX5PTGS2MAPTPOLBL3MBTL1 | |
| SCHEMBL24572812 | 0.68 | TNF (0.43) | MEN1KMT2APOLB | |
| SCHEMBL27509094 | 0.67 | MTNR1A (0.44) | PDE3BPDE3AGSK3BEGFRMTNR1A | |
| SCHEMBL3309764 | 0.66 | CA2 (0.45) | MTNR1AMTNR1BALDH1A1MAPT | |
| SCHEMBL13729900 | 0.66 | GSK3B (0.40) | PDE3BPDE3AGSK3BMTNR1AMTNR1B | |
| SCHEMBL2883982 | 0.65 | NQO2 (0.38) | ALOX5PTGS2MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404261-B2 | Compounds and compositions for treating conditions associated with cGAS | NOVARTIS AG (CH) | 2025-09-02 | — | — | US | disclosed |
| CN-116635382-A | Indole derivatives useful for treating cGAS-related disorders | 诺华股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230085472-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS | NOVARTIS PHARMA AG (CH) | 2023-03-16 | — | — | US | disclosed |
| WO-2022137085-A1 | INDOLE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS | NOVARTIS AG (CH) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404261-B2 | Compounds and compositions for treating conditions associated with cGAS | CGAS, TDP1, IAPP | PDE3B 129/4885PDE3A 91/4885ALOX5 2978/4885 |
| US-20230085472-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS | CGAS, TDP1, IAPP | PDE3B 129/4885PDE3A 91/4885ALOX5 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.